ProfileGDS5678 / 1428290_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 63% 62% 61% 62% 64% 62% 62% 62% 63% 63% 63% 59% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7789963
GSM967853U87-EV human glioblastoma xenograft - Control 23.7469863
GSM967854U87-EV human glioblastoma xenograft - Control 33.7366762
GSM967855U87-EV human glioblastoma xenograft - Control 43.6433661
GSM967856U87-EV human glioblastoma xenograft - Control 53.6778662
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8765364
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7964762
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7329562
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6769462
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7377763
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7337863
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7357863
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5613959
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8314764